side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare


With over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less


Show only
CMS Rus­sia has ad­vised Ovoca Bio Plc on IVIX ac­quis­i­tion
Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario, there will be no "trans­ition peri­od" but rather the UK.
CMS ad­vises Gilead Sci­ences on its agree­ment with Pharm­stand­ard...
New law im­proves pro­ced­ure for re­gis­ter­ing medi­cines in Rus­sia
On 15 June 2018, Fed­er­al Law No. 140-FZ “On Amend­ments to the Fed­er­al Law ‘On the Cir­cu­la­tion of Medi­cines’”* (the “Law”) came in­to force. It sim­pli­fies the re­gis­tra­tion of for­eign medi­cines, en­hances the op­por­tun­it­ies for con­tract man­u­fac­tur­ing in Rus­sia and.
Sergey Yuryev
The law on counter-sanc­tions now in force
New rules for de­scrib­ing medi­cines for pub­lic pro­cure­ment: more com­pet­i­tion...
The new rules* for de­scrib­ing medi­cines in tender doc­u­ment­a­tion for the pro­cure­ment of drugs by the state and mu­ni­cip­al au­thor­it­ies took ef­fect on 1 Janu­ary 2018. They are aimed at im­prov­ing the mar­ket for pub­lic pro­cure­ment of medi­cines through the ad­op­tion.
New rules for de­scrib­ing medi­cines for pub­lic pro­cure­ment:...
Rus­sia in­tro­duces li­ab­il­ity for fail­ure to ad­opt product re­call meas­ures
The amend­ments* to the Code on Ad­min­is­trat­ive Of­fences of the Rus­si­an Fed­er­a­tion came in­to force on 30 Ju­ly 2017. The amend­ments have es­tab­lished li­ab­il­ity for fail­ure to take product re­call meas­ures. Pre­vi­ously, there was no such li­ab­il­ity in the Rus­si­an le­gis­la­tion.
The new rules for medi­cines stor­age and trans­port­a­tion...
Rus­sia joins the Montreal Con­ven­tion of 1999
On 4 April, Fed­er­al Law No. 52-FZ* on Rus­sia’s join­ing the Con­ven­tion for the Uni­fic­a­tion of Cer­tain Rules for In­ter­na­tion­al Car­riage by Air 1999 (the “Montreal Con­ven­tion”) was pub­lished. Rus­sia joined the Con­ven­tion on the con­di­tion that it re­serves the right.
Rus­sia and the WTO: first re­view
The new rules for medi­cines stor­age and trans­port­a­tion in Rus­sia come...
The rules for prop­er stor­age and trans­port­a­tion of medi­cines* ap­proved by the Rus­si­an Min­istry of Pub­lic Health (the “Rules”) will take ef­fect from 1 March 2017. The doc­u­ment is aimed at pre­serving the qual­ity of medi­cines through­out the sup­ply chain, from.